Center for Scientific Review; Notice of Closed Meetings, 14600-14601 [07-1508]

Download as PDF 14600 Federal Register / Vol. 72, No. 59 / Wednesday, March 28, 2007 / Notices Place: The National Institutes of Health, 31 Center Drive, Building 31, C Wing, 6th Floor, Rooms 6–10, Bethesda, Maryland 20892. Contact Person: Ronna Hill, NSABB Program Assistant, 6705 Rockledge Drive, Bethesda, Maryland 20892, (301) 496–9838. This meeting will also be webcast. The draft meeting agenda and other information about NSABB, including information about access to the webcast and pre-registration, will be available at https:// ww.biosecurityboard.gov/meetings.asp. Any member of the public interested in presenting oral comments at the meeting may notify the Contact Person listed on this notice at least 10 days in advance of the meeting. Interested individuals and representatives of an organization may submit a letter of intent, a brief description of the organization represented and a short description of the oral presentation. Only one representative of an organization may be allowed to present oral comments. Both printed and electronic copies are requested for the record. In addition, any interested person may file written comments with the committee. All written comments must be received by April 2, 207 and should be sent via e-mail to nsabb@od.nih.gov with ‘‘NSABB Public Comment’’ as the subject line or by regular mail to 6705 Rockledge Drive, Suite 750, Bethesda, MD 20892, Attention Ronna Hill. The statement should include the name, address, telephone number and, when applicable, the business or professional affiliation of the interested person. In the interest of security, NIH has instituted stringent procedures for entrance onto the NIH campus. All visitor vehicles, including taxicabs, hotel, and airport shuttles will be inspected before being allowed on campus. Visitors will be asked to show one form of identification (for example, a government-issued photo ID’s driver’s license, or passport) and to state the purpose of their visit. Dated: March 20, 2007. Jennifer Spaeth, Director, Office of Federal Advisory Committee Policy. [FR Doc. 07–1511 Filed 3–27–07; 8:45 am] BILLING CODE 4140–07–M DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health sroberts on PROD1PC70 with NOTICES Center for Scientific Review; Notice of Closed Meetings Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meetings. The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose VerDate Aug<31>2005 17:09 Mar 27, 2007 Jkt 211001 confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. DEPARTMENT OF HEALTH AND HUMAN SERVICES Name of Committee: Center for Scientific Review Special Emphasis Panel, Small Business: Dentistry-Related. Date: April 12–13, 2007. Time: 8 a.m. to 9 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892, (Virtual Meeting). Contact Person: J. Terrell Hoffeld, DDS, PhD, Dental Officer, USPHS, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 4116, MSC 7816, Bethesda, MD 20892, (301) 435– 1781, th88q@nih.gov. Name of Committee: Center for Scientific Review Special Emphasis Panel, Bridges to the Future. Date: May 16, 2007. Time: 8 a.m. to 5 p.m. Agenda: To review and evaluate grant applications. Place: The River Inn, 924 25th Street, NW., Washington, DC 20037. Contact Person: Cathleen L. Cooper, PhD, Scientific Review Administrator, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 4208, MSC 7812, Bethesda, MD 20892, (301) 435– 3566, cooperc@csr.nih.gov. Name of Committee: Oncological Sciences Integrated Review Group, Cancer Molecular Pathobiology Study Section. Date: May 24–25, 2007. Time: 8 a.m. to 5 p.m. Agenda: To review and evaluate grant applications. Place: DoubleTree Hotel, 1515 Rhode Island Avenue, Washington, DC 20005. Contact Person: Elaine Sierra-Rivera, PhD, Scientific Review Administrator, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 6184, MSC 7804, Bethesda, MD 20892, (301) 435– 1779, riverase@csr.nih.gov. Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meetings. The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. (Catalogue of Federal Domestic Assistance Program Nos. 93.306, Comparative Medicine; 93.333, Clinical Research, 93.306, 93.333, 93.337, 93.393–93.396, 93.837–93.844, 93.846–93.878, 93.892, 93.893, National Institutes of Health, HHS) Dated: March 21, 2007. Jennifer Spaeth, Director, Office of Federal Advisory Committee Policy. [FR Doc. 07–1502 Filed 3–27–07; 8:45 am] BILLING CODE 4140–01–M PO 00000 Frm 00086 Fmt 4703 Sfmt 4703 National Institutes of Health Center for Scientific Review; Notice of Closed Meetings Name of Committee: Center for Scientific Review Special Emphasis Panel, AMCB Member Conflicts. Date: April 2, 2007. Time: 12 p.m. to 4 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892, (Telephone Conference Call). Contact Person: Eduardo A. Montalvo, PhD, Scientific Review Administrator, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 5212, MSC 7852, Bethesda, MD 20892, (301) 435– 1168, montalve@csr.nih.gov. This notice is being published less than 15 days prior to the meeting due to the timing limitations imposed by the review and funding cycle. Name of Committee: Center for Scientific Review Special Emphasis Panel, The Global Infectious Disease Meeting. Date: April 10, 2007. Time: 8 a.m. to 6 p.m. Agenda: To review and evaluate grant applications. Place: Georgetown Inn, 1310 Wisconsin Avenue, NW., Washington, DC 20007. Contact Person: Dan D. Gerendasy, PhD, Scientific Review Administrator, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 5132, MSC 7843, Bethesda, MD 20891, 301–594– 6830, gerendad@csr.nih.gov. This notice is being published less than 15 days prior to the meeting due to the timing limitations imposed by the review and funding cycle. (Catalogue of Federal Domestic Assistance Program Nos. 93.306, Comparative medicine; 93.333, Clinical Research, 93.306, 93.333, 93.337, 93.393–93.396, 93.837–93.844, 93.846–93.878, 93.892, 93.893, National Institutes of Health, HHS) E:\FR\FM\28MRN1.SGM 28MRN1 Federal Register / Vol. 72, No. 59 / Wednesday, March 28, 2007 / Notices Dated: March 20, 2007. Jennifer Spaeth, Director, Office of Federal Advisory Committee Policy. [FR Doc. 07–1508 Filed 3–27–07; 8:45 am] DATES: BILLING CODE 4140–01–M ADDRESSES: Only written comments and/or applications for a license which are received by the NIH Office of Technology Transfer on or before May 29, 2007 will be considered. DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health Prospective Grant of Exclusive License: Technologies Relating to SH2 Domain Binding Inhibitors and Inhibition of Cell Motility and Angiogenesis National Institutes of Health, Public Health Service, HHS. ACTION: Notice. sroberts on PROD1PC70 with NOTICES AGENCY: 17:09 Mar 27, 2007 Jkt 211001 These technologies relate to anti-cancer drugs that target the inhibition of specific enzymes in certain pathways that will interfere with a cell’s signal transduction processes. The current technologies include specific compounds that inhibit GRB2 SH2 domain binding. In addition, the technologies relate to how these compounds may inhibit cell motility and angiogenesis. The prospective exclusive license will be royalty bearing and will comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR part 404.7. The prospective exclusive license may be granted unless within sixty (60) days from the date of this published notice, the NIH receives written evidence and argument that establishes that the grant of the license would not be consistent with the requirements of 35 U.S.C. 209 and 37 CFR part 404.7. Applications for a license in the field of use filed in response to this notice will be treated as objections to the grant of the contemplated exclusive license. Comments and objections submitted to this notice will not be made available for public inspection and, to the extent permitted by law, will not be released under the Freedom of Information Act, 5 U.S.C. 552. SUPPLEMENTARY INFORMATION: SUMMARY: This is notice, in accordance with 35 U.S.C. 209(c)(1) and 37 CFR part 404.7(a)(1)(i), that the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an exclusive patent license to practice the inventions embodied in U.S. Patent Application No. 09/937,150, filed March 26, 2002, entitled ‘‘Phenylalanine Derivatives’’ [E–105–1999/0–US–07]; U.S. Patent Application No. 10/517,717, filed March 17, 2005, entitled ‘‘SH2 Domain Binding Inhibitors’’ [E–262–2000/1–US–03]; U.S. Patent Application No. 10/944,699, filed September 17, 2004, entitled ‘‘SH2 Domain Binding Inhibitors’’ [E–315– 2003/0–US–02]; PCT Patent Application PCT/US05/35246, filed September 30, 2005, entitled ‘‘A New Approach Toward Macrocyclization of Peptides’’ [E–327–2004/0–PCT–02]; U.S. Provisional Patent Application No. 60/ 867,307, filed November 27, 2006, entitled ‘‘Macrocyclic GRB2 SH2 Domain Binding Inhibitors Prepared Using Achiral Alkenyl Amines’’ [E– 305–2006/0–US–01]; U.S. Patent 6,977,241, issued December 20, 2005, entitled ‘‘SH2 Domain Binding Inhibitors’’ [E–262–2000/0–US–03]; U.S. Patent 7,132,392, issued November 11, 2006, entitled ‘‘Inhibition of Cell Motility and Angiogenesis by Inhibitors of the GRB2 SH2 Domain’’ [E–265– 1999/0–US–07]; to Angion Biomedica Corporation, having a place of business in Manhasset, New York. The patent rights in these inventions have been assigned to the United States of America. The prospective exclusive license territory may be worldwide, and the field of use may be limited to cancer and the modulation of angiogenesis in inflammatory disease. VerDate Aug<31>2005 Requests for copies of the patent application, inquiries, comments, and other materials relating to the contemplated exclusive license should be directed to: Adaku Nwachukwu, J.D., Technology Licensing Specialist, Office of Technology Transfer, National Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, MD 20852–3804; Telephone: (301) 435– 5560; Facsimile: (301) 402–0220; E-mail: madua@mail.nih.gov. Dated: March 16, 2007. Steven M. Ferguson, Director, Division of Technology Development and Transfer, Office of Technology Transfer, National Institutes of Health. [FR Doc. E7–5674 Filed 3–27–07; 8:45 am] BILLING CODE 4140–01–P PO 00000 Frm 00087 Fmt 4703 Sfmt 4703 14601 DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health Prospective Grant of Exclusive License: The Catalytic Moiety of the Glucose-6-Phosphatase System: The Gene and Protein and Related Mutations National Institutes of Health, Public Health Service, HHS. ACTION: Notice. AGENCY: SUMMARY: This is notice, in accordance with 35 U.S.C. 209(c)(1) and 37 CFR 404.7(a)(1)(i), that the National Institutes of Health (NIH), Department of Health and Human Services, is contemplating the grant of an exclusive license worldwide to practice the invention embodied in U.S. Patent Number 5,460,942 issued October 24, 1995 entitled, ‘‘The Catalytic Moiety of the Glucose-6-Phosphatase System: the Gene and Protein and Related Mutations’’ (HHS Ref. No. E–179–1993/ 0–US–01) to GlyGenix, Inc., having a place of business in Cheshire, CT 06410. The contemplated exclusive license may be limited to the following field of use: an FDA-approvable human therapeutic for Glycogen Storage Disease Type Ia. The United States of America is the assignee of the patent rights in this invention. DATES: Only written comments and/or application for a license which are received by the NIH Office of Technology Transfer on or before May 29, 2007 will be considered. ADDRESSES: Requests for a copy of the patent, inquiries, comments, and other materials relating to the contemplated license should be directed to: Tara L. Kirby, PhD, Technology Licensing Specialist, Office of Technology Transfer, National Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, MD 20852–3804; Telephone: 301–435–4426; Facsimile: 301–402– 0220; E-mail: kirbyt@mail.nih.gov. SUPPLEMENTARY INFORMATION: Glycogen storage diseases result from at least 10 different genetic defects in proteins required by glycogen metabolism. Glycogen storage disease Type Ia (GSD, also known as von Gierke disease) is defined as the deficiency of glucose-6phosphatase (G–6–Pase) which is normally present in liver, kidney, and intestine. Glycogen storage disease Type la is inherited by one per 100,000 people as an autosomal recessive trait and is usually manifested during the first twelve months of life by symptomatic hypoglycemia, or by the recognition of hepatomegaly. In E:\FR\FM\28MRN1.SGM 28MRN1

Agencies

[Federal Register Volume 72, Number 59 (Wednesday, March 28, 2007)]
[Notices]
[Pages 14600-14601]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 07-1508]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Center for Scientific Review; Notice of Closed Meetings

    Pursuant to section 10(d) of the Federal Advisory Committee Act, as 
amended (5 U.S.C. Appendix 2), notice is hereby given of the following 
meetings.
    The meetings will be closed to the public in accordance with the 
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 
U.S.C., as amended. The grant applications and the discussions could 
disclose confidential trade secrets or commercial property such as 
patentable material, and personal information concerning individuals 
associated with the grant applications, the disclosure of which would 
constitute a clearly unwarranted invasion of personal privacy.

    Name of Committee: Center for Scientific Review Special Emphasis 
Panel, AMCB Member Conflicts.
    Date: April 2, 2007.
    Time: 12 p.m. to 4 p.m.
    Agenda: To review and evaluate grant applications.
    Place: National Institutes of Health, 6701 Rockledge Drive, 
Bethesda, MD 20892, (Telephone Conference Call).
    Contact Person: Eduardo A. Montalvo, PhD, Scientific Review 
Administrator, Center for Scientific Review, National Institutes of 
Health, 6701 Rockledge Drive, Room 5212, MSC 7852, Bethesda, MD 
20892, (301) 435-1168, montalve@csr.nih.gov.
    This notice is being published less than 15 days prior to the 
meeting due to the timing limitations imposed by the review and 
funding cycle.

    Name of Committee: Center for Scientific Review Special Emphasis 
Panel, The Global Infectious Disease Meeting.
    Date: April 10, 2007.
    Time: 8 a.m. to 6 p.m.
    Agenda: To review and evaluate grant applications.
    Place: Georgetown Inn, 1310 Wisconsin Avenue, NW., Washington, 
DC 20007.
    Contact Person: Dan D. Gerendasy, PhD, Scientific Review 
Administrator, Center for Scientific Review, National Institutes of 
Health, 6701 Rockledge Drive, Room 5132, MSC 7843, Bethesda, MD 
20891, 301-594-6830, gerendad@csr.nih.gov.
    This notice is being published less than 15 days prior to the 
meeting due to the timing limitations imposed by the review and 
funding cycle.

(Catalogue of Federal Domestic Assistance Program Nos. 93.306, 
Comparative medicine; 93.333, Clinical Research, 93.306, 93.333, 
93.337, 93.393-93.396, 93.837-93.844, 93.846-93.878, 93.892, 93.893, 
National Institutes of Health, HHS)



[[Page 14601]]


    Dated: March 20, 2007.
Jennifer Spaeth,
Director, Office of Federal Advisory Committee Policy.
[FR Doc. 07-1508 Filed 3-27-07; 8:45 am]
BILLING CODE 4140-01-M

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.